1 |
Yang Z, Liang X, Fu Y, et al. Identification of AUNIP as a candidate diagnostic and prognostic biomarker for oral squamous cell carcinoma[J]. EBioMedicine, 2019, 47: 44-57.
|
2 |
Yen CJ, Tsou HH, Hsieh CY, et al. Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: final analysis of a phase 2 clinical trial[J]. Head Neck, 2019, 41(6): 1703-1712.
|
3 |
Guo J, Zhou S, Huang P, et al. NNK-mediated upregulation of DEPDC1 stimulates the progression of oral squamous cell carcinoma by inhibiting CYP27B1 expression[J]. Am J Cancer Res, 2020, 10(6): 1745-1760.
|
4 |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3): 209-249.
|
5 |
Fadaka AO, Pretorius A, Klein A. Biomarkers for stratification in colorectal cancer: microRNAs[J]. Cancer Control, 2019, 26(1): 1073274819862784.
|
6 |
O’Connell RM, Rao DS, Chaudhuri AA, et al. Physiological and pathological roles for microRNAs in the immune system[J]. Nat Rev Immunol, 2010, 10(2): 111-122.
|
7 |
Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways[J]. Nat Rev Mol Cell Biol, 2019, 20(1): 5-20.
|
8 |
Wang S, Claret FX, Wu W. MicroRNAs as therapeutic targets in nasopharyngeal carcinoma[J]. Front Oncol, 2019, 9: 756.
|
9 |
Wang YL, Shen Y, Xu JP, et al. Pterostilbene suppresses human endometrial cancer cells in vitro by down-regula-ting miR-663b[J]. Acta Pharmacol Sin, 2017, 38(10): 1394-1400.
|
10 |
Wang M, Jia M, Yuan K. MicroRNA-663b promotes cell proliferation and epithelial mesenchymal transition by directly targeting SMAD7 in nasopharyngeal carcinoma[J]. Exp Ther Med, 2018, 16(4): 3129-3134.
|
11 |
Luo Y, Li W, Ling Z, et al. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells[J]. Cancer Med, 2020, 9(10): 3489-3499.
|
12 |
Shu Y, Ye W, Gu YL, et al. Blockade of miR-663b inhibits cell proliferation and induces apoptosis in osteosarcoma via regulating TP73 expression[J]. Bratisl Lek Listy, 2018, 119(1): 41-46.
|
13 |
Du M, Shi D, Yuan L, et al. Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer[J]. Sci Rep, 2015, 5: 10437.
|
14 |
Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities[J]. Front Med, 2018, 12(4): 361-373.
|
15 |
Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology[J]. Pathology, 2007, 39(3): 305-318.
|
16 |
Wang Z, Divanyan A, Jourd’heuil FL, et al. Vimentin expression is required for the development of EMT-related renal fibrosis following unilateral ureteral obstruction in mice[J]. Am J Physiol Renal Physiol, 2018, 315(4): F769-F780.
|
17 |
Mukai T, Gallant R, Ishida S, et al. Loss of SH3 domain-binding protein 2 function suppresses bone destruction in tumor necrosis factor-driven and collagen-induced arthritis in mice[J]. Arthritis Rheumatol, 2015, 67(3): 656-667.
|
18 |
Kawahara K, Mukai T, Iseki M, et al. SH3BP2 Deficiency Ameliorates Murine Systemic Lupus Erythematosus[J]. Int J Mol Sci, 2021,22(8): 4169.
|
19 |
Lin L, Chamberlain L, Pak ML, et al. A large-scale RNAi-based mouse tumorigenesis screen identifies new lung cancer tumor suppressors that repress FGFR signaling[J]. Cancer Discov, 2014, 4(10): 1168-1181.
|
20 |
Kittaka M, Yoshimoto T, Schlosser C, et al. Alveolar bone protection by targeting the SH3BP2-SYK axis in osteoclasts[J]. J Bone Miner Res, 2020, 35(2): 382-395.
|